27 Analysis of next generation transcriptome sequencing data of prostate cancer 28 identified a novel gene fusion formed by the fusion of a protein coding gene (KLK4) with a 29 non-coding pseudogene (KLKP1) and expression of its cognate protein. Screening of 659 30 prostate cancer TMA showed about 32% of positive cases predominantly expressed in 31 higher Gleason grade tumors. Concomitant expression with ERG but not with SPINK1 and 32 other ETS fusion positive tumors. Fusion gene expression potentially regulated by AR and 33 ERG. Antibody specific to the KLK4-KLKP1 fusion protein was validated by 34 immunohistochemistry and western blot methods. Oncogenic properties were validated by 35 in vitro and in vivo functional studies. Clinical data analysis shows significant association 36 with prostate cancer in young men and overall survival analysis indicate favorable prognosis. 37 Non-invasive detection in urine samples has been confirmed. Taken together, we present a 38 novel biomarker for routine screening of high Gleason grade prostate cancer at diagnosis. 39 40 SIGNIFICANCE 41
6 specific to distinct patient subgroups, are required as alternatives for both initial cancer diagnosis 95 and distinguishing aggressive cancer from indolent disease. 96
Although several recurrent molecular alterations have been identified in a subset of 97 prostate cancer cases, the genetic aberrations in prostate cancer patients negative for all the 98 known molecular makers remain to be studied. Moreover, most prostate cancer molecular studies 99 have been carried out on Caucasian American patients with little representation from the African 100 American (AA) population [17] . Given the unique ancestral background of AAs and the 101 aggressive nature of prostate cancer, the genetic underpinnings to understand the racial disparity 102 in the incidence of prostate cancer markers is not well studied. Therefore, the study of additional 103 molecular aberrations using large cohorts of a racially diverse population is a pressing need in 104 prostate cancer research. In addition to identifying subtype specific prostate cancer diagnostic 105 and prognostic markers, such studies may also facilitate the development of novel therapeutic 106 approaches by uncovering molecular alterations, which may be pharmacologically targeted in 107 distinct patient subgroups. 108 7 with a predicted chimeric protein of 164 amino acids, of which 55 amino acids are derived from 118 the pseudogene part due to a shift in the open reading frame of the fusion formed by trans-119 splicing mechanism rather than chromosomal rearrangement [18] . Although a few pseudogenes 120 have been previously reported to be expressed as proteins [20, 21] , KLK4-KLKP1 is a rare 121 example where gene fusion leading to conversion of a non-coding pseudogene to a protein-122 coding gene. Further studies showed that KLK4-KLKP1 fusion is both prostate tissue and cancer 123 specific, suggesting a possible role in prostate cancer formation [18] . Both the prostate cancer 124 specific expression and the intriguing nature of the KLK4-KLKP1 fusion warrant further 125 8 quantitative PCR (qRT-PCR) analysis of prostate cancer samples, prostate cell lines, benign 141 prostate tissues and other solid cancers revealed that KLK4-KLKP1 fusion transcript is prostate 142 cancer specific and expressed in a subset of cases [18] . However, the study included only a 143 limited number of prostate cancer samples (n = 36) and the occurrence of KLK4-KLKP1 in a 144 large, racially inclusive cohort must be explored to determine the prevalence of KLK4-KLKP1 in 145 the prostate cancer patient population. Therefore, we studied the expression of KLK4-KLKP1 on 146 a larger patient cohort using fusion transcript specific anti-sense oligonucleotide probe by RNA 147 in situ hybridization (RNA-ISH). Specifically, we constructed tissue microarrays (TMAs) using 148 prostate cancer tissues obtained from 659 radical prostatectomy (RP) specimens at the Henry 149 Ford Health Systems. The cohort was racially inclusive with 380 Caucasian, 250 AA and 29 150 patients belonging to other racial groups. Each TMA contained 3 cores obtained from different 151 regions of the RP prostate from each patient (Supplementary Fig. S3 ). The individual tissue 152 cores in each patient were reviewed and the highest tumor grade observed was assigned to each 153 case. Thus the TMAs included 612 patient cases with all cores carrying prostate cancer (Gleason 154 grade group 1 [3 + 3 = 6] -110, Gleason 1C) and remaining cases were "0" or negative, suggesting varying expression levels among 168 patients. To further confirm that KLK4-KLKP1 is specific to prostate cancer, we then explored 169 the association of KLK4-KLKP1 RNA-ISH signal with Gleason grade by using Pearson's chi-170 square test. The results showed that KLK4-KLKP1 is exclusively expressed in prostate cancer 171 tissues compared to benign, high grade prostate intraepithelial neoplasia and atypical prostate 172 tissues ( Fig. 1D, Fig. 1E , and Table 1 ), confirming that KLK4-KLKP1 expression is prostate 173 cancer specific. Additionally, we also analyzed if KLK4-KLKP1 expression is associated with 174
Gleason grade group and found no associations with distinct Gleason grade groups ( Table 2) . 175
Next, we investigated if KLK4-KLKP1 fusion displays racial disparity in the incidence. 176
The 209 positive cases included 128 Caucasian Americans (34%), 69 AAs (28%) and 12 patients 177 from other races (41.4%). Pearson's chi-square test analysis revealed that prevalence of KLK4-178 KLKP1 is high in Caucasian American compared with AA patients but not statistically 179 significant ( Table 3 and Supplementary Fig. S4 ), demonstrating no racial bias in the incidence. 180
We also explored if KLK4-KLKP1 expression is related with patient age. We categorized the 181 patients into 2 groups as young (age ranging from 40 to 50 years) and old (age ranging from 51 182 to 83 years). Pearson's chi-square test showed significantly higher expression of KLK4-KLKP1 183 in young age group compared to the old age group ( Fig. 1F and Table 4 ). 184
The other common prostate cancer specific mutations such as ETS gene fusions and 10 analyzed the association of KLK4-KLKP1 fusion expression with ETS gene fusions and SPINK1 187 expression. We screened the same set of TMAs by using dual immunohistochemistry (IHC) for 188 ERG and SPINK1 and dual RNA-ISH for ETV1, ETV4 and ETV5. By using Pearson's chi-square 189 test, we observed that KLK4-KLKP1 expression is associated with ERG+ cases (Fig. 1G of the fusion transcript was confirmed by qRT-PCR using fusion specific primers ( Fig. 2A) . Cell 210 lysates were analyzed by western blotting using an anti-N-FLAG antibody. Importantly, we 211 observed a FLAG-specific protein band around 17kDA ( Fig. 2B) , confirming the expression of 212 KLK4-KLKP1 as a full-length protein. For additional validation, we also checked the expression 213 of N-FLAG-tagged KLK4-KLKP1 using the anti-FLAG antibody in the normal prostate cell line 214 RWPE-1, transfected with and without N-FLAG-tagged KLK4-KLKP1 adenovirus construct. 215
Notably, we detected anti-FLAG specific protein band only in the transfected RWPE1 cells 216 ( Supplementary Fig. S6 ). Furthermore, we also developed a KLK4-KLKP1 specific polyclonal 217 antibody (Eurogentech, Seraing, Belgium) using the antigenic peptide "CTISATSSARTS" ( Table 6 ). Then, we selected one of the PDX tissues (MDA PCa 153-7) expressing high 228 levels of KLK4-KLKP1 and one with no detectable levels of KLK4-KLKP1 (MDA PCA 144-13). 229
After protein isolation and separation on SDS-PAGE, the lysates were probed with the KLK4-230 KLKP1 specific antibody using western blot. Importantly, we observed a protein band around 12 expression of KLK4-KLKP1 fusion protein in metastatic prostate cancer patients. Additionally, 233
we also screened the expression of KLK4-KLKP1 in xenograft tissues using IHC with the KLK4-234 KLKP1 specific antibody. While KLK4-KLKP1 expression was observed in qRT-PCR positive 235 PDX tissues, minimal or no KLK4-KLKP1 IHC signal was seen in qRT-PCR negative xenografts 236 ( Fig. 2D) , further suggesting the presence of KLK4-KLKP1 protein in a subset of prostate cancer 237 patients. Comparison of IHC results with RNA -ISH positive and negative tissue showed 238 specificity of the antibody to KLK4-KLKP1 RNA-ISH positive tissue only ( Fig.2G ). 239
Given the exclusive expression of KLK4-KLKP1 in prostate cancer, next we explored the 240 functions of KLK4-KLKP1 by studying the oncogenic properties of the fusion gene. Specifically, 241
we established RWPE-1 cells with stable expression of KLK4-KLKP1 by transfection with 242 lentiviral constructs carrying FLAG-tagged KLK4-KLKP1. As controls, cells stably transfected 243 with a LACZ control (LACZ) and un-transfected RWPE-1 cells were used. We first confirmed 244 the expression of KLK4-KLKP1 by qRT-PCR. The results showed significant expression of 245 KLK4-KLKP1 in transfected cells compared to both the un-transfected cells and the LACZ 246 control ( Fig. 3A) . Then we investigated the effect of KLK4-KLKP1 on cell proliferation by 247 measuring the number of cells using a Coulter particle counter. Compared to the un-transfected 248 cells and the LACZ control, a notable increase in the cell number was seen over time in KLK4-249 KLKP1 transfected cells ( Fig. 3B) , indicating a role of KLK4-KLKP1 on cell proliferation. Next, 250
we studied the effect of KLK4-KLKP1 in cell invasion using the Matrigel invasion assay. 251 Importantly, a significant increase in the number of invaded cells was observed with KLK4-252 KLKP1 transfected cells compared to both the un-transfected and the LACZ control ( Fig. 3C) . 253
For additional validation, we also transiently transfected PrEC, another normal prostate cell line 254 with KLK4-KLKP1. As controls, un-transfected cells and cells transfected with a LACZ control were used. Additionally, we also used cells transfected with EZH2, which has been shown to 256 increase invasion of prostate cancer and other cancer cells [29, 30] as a positive control. The 257 invasion of cells was then examined by the Matrigel invasion assay. Like RWPE-1, PrEC cells 258 also showed a significant increase in the number of invaded cells compared to both the un-259 transfected and the LACZ control ( Fig. 3D) . As expected, cells transfected with EZH2 also 260 demonstrated increased invasion compared to the LACZ control and the un-transfected cells 261 ( Fig. 3D) . In all, our studies indicate that KLK4-KLKP1 promote both cell proliferation and 262 invasion of prostate cells, suggesting an oncogenic role for KLK4-KLKP1 fusion. 263
In order to further understand the oncogenic properties of KLK4-KLKP1, we also studied 264 the effects of KLK4-KLKP1 fusion on intravasation and tumor formation using the chicken 265 chorioallantoic membrane (CAM) in vivo assay [31, 32] . We implanted eggs with RWPE-1 cells 266 stably expressing KLK4-KLKP1 and then checked for the presence of intravasated cells in the 267 lower CAM by using quantitative human Alu-specific PCR. As controls, eggs implanted with 268 either un-transfected cells or cells stably transfected with a LACZ control were used. Notably, 269
we observed a marked intravasation by KLK4-KLKP1 transfected cells in the lower CAM 270 compared to both un-transfected cells and LACZ control ( Fig. 3E) . Additionally, we also 271 isolated and weighed the extraembryonic tumors from eggs implanted with either KLK4-KLKP1 272 transfected cells or controls. The tumors isolated from eggs implanted with cells expressing 273 KLK4-KLKP1 showed significantly higher weight than the tumors isolated from eggs treated 274 with the un-transfected cells and the LACZ control ( Fig. 3F) . Overall, the results establish that 275 KLK4-KLKP1 drives intravasation and tumor formation in prostate cells, indicating a potential 14 Further, we investigated the molecular mechanisms underlying the oncogenic functions 278 of KLK4-KLKP1 fusion. We conducted a gene expression microarray analysis using RWPE-1 279 cells stably transfected with KLK4-KLKP1. As the control, cells transfected with LACZ control 280 were used. After RNA isolation, and microarray analysis, we observed a significant number of 281 genes expressed differently between the RWPE-1 cells transfected with KLK4-KLKP1 and the 282 LACZ control. We selected the genes showing a fold change value of more than 1 in 2 283 independent replicates and generated a heat map with the top 100 genes differentially expressed 284 ( Fig. 4A) . We noted genes both upregulated and downregulated in cells expressing the KLK4-285 KLKP1 fusion, suggesting a possible function for KLK4-KLKP1 in gene expression regulation. 286
Further, we also carried out a gene set enrichment analysis [33] to explore any overlap between 287 the differentially expressed genes observed with KLK4-KLKP1 transfection and other curated 288 gene sets. Importantly, we noted enrichment of 2 curated gene sets, one involving genes 289 upregulated in endometroid endometrial metastatic tumor and the other containing genes 290 overexpressed in melanoma metastatic cancer ( Fig. 4B) , indicating that the genes affected by 291 KLK4-KLKP1 are associated with metastatic cancer. As a further step, we also carried out a 292 KEGG pathway analysis using the DAVID tool [34] . The genes differentially affected by KLK4-293 KLKP1 were shown to be associated with several cancer-related pathways ( Fig. 4C) , further 294
implying that KLK4-KLKP1 may regulate the expression of genes involved in cancer and 295 metastasis. 296
Given the well-established role of androgen receptor (AR) in gene expression in prostate 297 cancer [35] , we also explored if AR is driving the expression of KLK4-KLKP1 in prostate cancer. 298
Additionally, since we observed concurrent expression of ERG with KLK4-KLKP1 ( Fig. 1G) , 299
we also studied if ERG is involved in the expression of KLK4-KLKP1. Therefore, to identify any AR or ERG binding sequences on KLK4 or KLKP1, we examined data from a previous study 301 where a chromatin immunoprecipitation assay was carried out using antibodies specific to AR 302 and ERG [36] . Notably, we observed both AR and ERG binding sites at the fusion junction of 303 KLKP1 (Supplementary Fig. S8 ), suggesting that both AR and ERG may modulate the 304 expression of KLK4-KLKP1 during prostate cancer formation. 305
For further characterization of the functional role of KLK4-KLKP1, we also studied the 306 cellular localization of KLK4-KLKP1. We carried out immunofluorescence studies of RWPE-1 307 cells transfected with adeno-FLAG tagged-KLK4-KLKP1 using fluorescent anti-FLAG antibody. 308
As a control, cells transfected with adeno-LacZ were used. While cells transfected with adeno-309
Lacz showed minimal immunofluorescence as expected, notably, we observed colocalization of 310 Therefore, to further explore the potential utility of KLK4-KLKP1 as a prostate cancer marker, 315 we investigated the association between KLK4-KLKP1 expression and preoperative PSA of the 316 659 patients in our cohort. Specifically, we performed a t-test to evaluate difference in log-317 transformed preoperative PSA between cases with and without KLK4-KLKP1 expression. 318
Interestingly, patients with KLK4-KLKP1 expression showed slightly lower preoperative PSA 319 values compared to patients without KLK4-KLKP1 expression ( Supplementary Fig. S10 ). As a 320 further step, we also analyzed the association between KLK4-KLKP1 and the time to biochemical 321 recurrence, using multivariable Cox regression model. Patients with KLK4-KLKP1 showed a 322 lower risk of biochemical recurrence (HR = 0.58; Supplementary Fig. S11 ) after adjusting for 16 age, Gleason grade, and tumor stage. However, the difference in recurrence was not statistically 324 significant (p = 0.12), possibly due to small power as the number of patients showing recurrence 325 was small (n = 49). Additionally, we also analyzed the association of KLK4-KLKP1 with other 326 clinical and pathological parameters such as family history, tumor stage, tumor volume, 327 metastasis to lymph nodes, perineural invasion and presence of lymph vascular invasion using 328
Pearson's chi-square test. No statistically significant association was observed between KLK4-329 KLKP1 and the clinicopathological variables. Lastly, like TMPRSS2-ERG gene fusions in 330 prostate cancer, we explored the feasibility of detecting KLK4-KLKP1 in urine samples of 331 prostate cancer patients for noninvasive detection of this marker. We collected urine samples 332 from 90 unselected prostate cancer patients. All patients had confirmed prostate cancer, with 333 most having metastatic or biochemically recurrent disease. Then we screened for KLK4-KLKP1 334 transcript using qRT-PCR. As a positive control, RWPE-1 cells stably expressing KLK4-KLKP1 335 was used. Importantly, KLK4-KLKP1 expression was detected in 15 out of 90 (17%) patient 336 samples ( Supplementary Fig. S12 ), suggesting the potential for noninvasive detection in patient 337 urine samples. Overall, our study establishes KLK4-KLKP1 as a recurrent chimeric transcript 338 exclusively expressed in prostate cancer tissues with implications on disease progression and 339 feasibility of being noninvasively detected in patient urine samples. 340
341

DISCUSSION 342
Given the complex heterogeneous nature of prostate cancer, the identification of distinct 343 patient subgroups based on molecular markers is a necessary step towards targeted disease 344 management. Therefore, in this study we further explored and characterized a pseudogene 345 associated gene fusion KLK4-KLKP1. We established that KLK4-KLKP1 is a recurrent, prostate cancer exclusive fusion transcript that occurs at a significant incidence rate (32%) among 347 prostate cancer patients. Similar to other distinct molecular aberrations such as ETS 348 KLKP1 may play a role in transcription during prostate cancer formation. In agreement with a 362 role in transcriptional regulation, KLK4-KLKP1 was also seen to be localized in the nucleus. 363
Furthermore, both ERG and AR were found to have binding sites on KLKP1, indicating that 364 KLK4-KLKP1 expression may be ERG and AR modulated. Finally, we showed that KLK4-365 KLKP1 can be easily detected in patient urine samples, suggesting the feasibility for possible 366 future use as a biomarker for early detection of high Gleason grade prostate cancer. Altogether, 367 our study establishes KLK4-KLKP1 as a novel player in a subset of prostate cancer cases with 368 likely roles in tumor formation.
18
Long thought to be junk or nonfunctional units of the human genome, pseudogenes have 370 been recently acknowledged to have key cellular roles, particularly in diseases such as cancer 371
[37]. While some pseudogenes are known to be transcribed into non-coding RNA [37], a few 372 pseudogenes have been shown to be even express proteins [20] . Studies have revealed that 373 several different variants of KLKP1 pseudogene are transcribed exclusively in prostate tissues 374 ( Supplementary Fig. S1 ) in an androgen regulated manner [21, 38] . Of the different variants, at 375 least one KLKP1 variant has been shown to be expressed as a protein in a transfected cell, 376
although not in vivo [21] . Even though the variant chimeric transcripts of KLK4-KLKP1 has 377 been previously described [39, 40] , it has not been reported to be expressed as a protein and the 378 functional characteristics have not been validated. Importantly, we verified that KLK4-KLKP1 is 379 expressed as a full-length protein in both transfected cells and endogenously in castration 380 resistant prostate cancer (PDX), suggesting the occurrence in prostate cancer tissues. In contrast 381 to KLK4, which is overexpressed in prostate cancer with roles in cell proliferation, migration and 382 cancer metastasis [41-43], all KLKP1 variants are known to be expressed more in normal 383 prostate tissues compared to prostate cancer [21, 38] . However, KLK4-KLKP1 is exclusively 384 expressed in prostate cancer with co-occurrence with ERG+ tumors. Thus, our results indicate 385 novel complexity in the KLK4 and KLKP1 locus and hint at differential expression of the loci in 386 prostate cancer cells compared to normal prostate cells. Given the presence of AR and ERG 387 binding sites on KLKP1 and the previous reports demonstrating AR regulation of KLKP1 388 expression [21, 38] , it is likely that prostate cancer specific expression of KLK4-KLKP1 is 389 modulated by AR and ERG. Furthermore, additional variants of KLK4-KLKP1, which are 390 different from the KLK4-KLKP1 transcript observed in prostate cancer, have also been reported 391 in renal cell cancer [40] . While the alternative KLK4-KLKP1 transcripts were found to occur in a considerable subset of renal cell cancer cases (27%), none of the variants were shown to be 393 expressed as proteins. Thus KLK4-KLKP1 may be spliced and expressed differently in a tissue 394 specific manner in distinct cancers. Taken together, our results suggest that KLK4 and KLKP1 395 may be a diverse locus that undergo differential splicing and transcription with functional 396 implications in cancer. Consequently, our work highlights unprecedented roles of pseudogenes 397 and complex molecular events involved in cancer. 398
In agreement with previous reports indicating significant molecular heterogeneity among 399 prostate cancer cases [7], KLK4-KLKP1 was expressed only in a subset of prostate cancer 400 patients (32%). Additionally, KLK4-KLKP1 expression was significantly higher in younger 401 patients compared to older prostate cancer patients. Given the oncogenic properties and the 402 transcriptional changes observed with KLK4-KLKP1, our results suggest that distinct molecular 403 changes may dictate unique prostate cancer clinical outcomes among patients. Thus, our study 404 further emphasizes the need for subtype specific molecular markers in prostate cancer control. 405
In addition to enhancing cell proliferation, invasion and tumor formation, KLK4-KLKP1 also 406 caused marked changes in gene expression. Notably, genes affected by KLK4-KLKP1 were 407 cancer-related and were involved in metastasis of other cancers, implicating a functional role for 408 KLK4-KLKP1 in prostate cancer. Additionally, ERG was found to have a binding site on KLK4-409 KLKP1. Given that ERG expression was associated with KLK4-KLKP1, ERG may bind to the 410 visualized on an imaging system (ChemiDoc, BIO-RAD) using a chemiluminescence developing 499 kit (Clarity™ Western ECL Blotting Substrates, BIO-RAD, catalog #1705060). 500
Measurement of cell proliferation 501
Cell proliferation was measured by cell counting. For this, stable RWPE-1 cells 502 overexpressing KLK4-KLKP1 (DDK-tagged) or lacZ were used. The cells were seeded at a 503 density of 10 000 cells per well in 24-well plates (n=3). Next, the cells were trypsinized and 504 counted at specified time points by Z2 Coulter particle counter (Beckman Coulter, Brea, CA, 24 USA). LacZ cells were served as controls. Each experiment has been performed with three 506 replicates per sample. 507
Matrigel invasion assay 508
Matrigel invasion assays were performed using BD BioCoat Matrigel matrix (Corning Life  509 Sciences, Tewksbury, MA, USA). The parental and transfected clones of RWPE-1 and PrEC cells 510 were seeded at 1 × 105 cells in serum-free medium in the upper chamber of a 24-well culture plate. 511
The lower chamber containing respective medium was supplemented with 10% serum as a 512 chemoattractant. After 48 h, the non-invading cells and Matrigel matrix from the upper side of the 513 chamber were gently wiped with a cotton swab. Invasive cells located on the lower side of the 514 chamber were stained with 0.2% crystal violet in methanol, air-dried and photographed using an 515 inverted microscope (4x). Invasion was quantified by colorimetric assay or by counting the number 516 of cells. For colorimetric assays, the inserts were treated with 150 μl of 10% acetic acid and the 517 absorbance measured at 560 nm. 518
Chicken Chorioallantoic Membrane Assay (CAM) assay 519
CAM assay was performed as described earlier [31] . Briefly, fertilized eggs were incubated 520 in a rotary humidified incubator at 38°C for 10 days. CAM was dropped by making two holes, one 521 through the eggshell into the air sac and a second hole near the allantoic vein that penetrates the 522 eggshell membrane but not the CAM. Subsequently a cutoff wheel (Dremel) was used to cut a 1 523 cm2 window to expose the underlying CAM near the allantoic vein. After 3 days of implanting 524 the 2*10 6 cells in 50 ul medium on the top of each egg, lower CAM was harvested and analyzed 525 for the presence of tumor cells by quantitative human Alu-specific PCR. Genomic DNA from 526 lower CAM and livers were prepared using Puregene DNA purification system (Qiagen USA) and 527 quantification of human-Alu was performed as described (Ref). After 7 days of implantation, 528 extraembryonic tumors were isolated and weighed. An average of 8 eggs per group was used in ea 529
Gene expression microarray analysis 530
Two-channel microarray experiment was performed with two replicates using the Agilent 531
Whole Human Genome Oligo Microarray (Agilent, catalog #G4851C Whole Human Genome 532 Microarray 8x60K). Raw data from each replicates were independently processed using 533 Bioconductor packages. "agilp" Bioconductor package (1) 
